FCRL5 and neoplasm: Generally, FcRH5 expression levels in tumor cells was not significantly elevated compared with normal plasma cells, suggesting that developing a tumor cell-selective, normal plasma cell-sparing anti-FcRH5/CD3 TDB may not be feasible.